IN8BIO, INC. Accrued Professional Fees
IN8BIO, INC. (INAB) had Accrued Professional Fees of $264.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent · last filed 2024-11-12
- 2024-09-30: Accrued Professional Fees $264.00K.
- 2023-12-31: Accrued Professional Fees $32.00K.
| Period end | Accrued Professional Fees |
|---|---|
| 2024-09-30 | $264.00K 10-Q · filed 2024-11-12 |
| 2023-12-31 | $32.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |